News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Veralto (VLTO) is gaining investor attention due to improved earnings estimates, a positive outlook driven by U.S. infrastructure and semiconductor demand, and its recent acquisition of In-Situ Inc. While the stock's share price has seen recent positive momentum, its P/E ratio is currently above …
Molson Coors's Q2 Earnings Call: Our Top 5 Analyst Questions Molson Coors' Q2 results were shaped by external pressures that weighed on sales and profitability, with revenue meeting Wall Street's expectations but operating margin declining significantly from the prior year. Management attributed the performance …
5 Insightful Analyst Questions From Monster's Q2 Earnings Call Monster's second-quarter performance was marked by robust top-line growth, as revenue exceeded Wall Street's expectations, but the market responded negatively, reflecting concerns about profitability and expense trends. Management attributed the quarter's strong sales to broad-based …
Sharemaestro market context Trend signal active 52 weeks +36.1% · Next-week setup negative 44.0%Wall Street Zen downgraded Verastem (NASDAQ:VSTM) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $13.83. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting a loss of $0.35 per share against an estimated …
SR One-affiliated funds have reduced their stake in Veradermics (MANE) by selling 321,749 common shares at $104.30 per share, totaling approximately $33.5 million. Following this transaction, SR One's combined holdings represent 4.9% of Veradermics' outstanding common stock, bringing their beneficial ownership below the 5% …
Veracyte Inc (VCYT) shares dropped 3.2% to $41.25, placing it 6.7% overvalued compared to its GF Value™ of $38.65, despite a strong GF Score™ of 80/100. Insider selling totaling $9.7 million over the past three months, with no reported buying, suggests caution for potential …
Entities linked to Veradermics director John W. Childs sold 100,000 shares of common stock on August 12, 2026, through indirect holdings. These sales were conducted via the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., at weighted-average prices ranging from …
Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …
T. Rowe Price Investment Management has disclosed a 5.6% stake in Veralto Corp (VLTO), amounting to 13,722,619 shares of common stock as of June 30, 2026. This ownership, reported via a Schedule 13G filing, indicates sole voting power over 13,257,448 shares and sole dispositive …
Armistice Capital, LLC and Steven Boyd have reported a significant beneficial ownership stake of 7.76% in Verastem, Inc. (VSTM), totaling 7,024,000 shares. This ownership is held with shared voting and dispositive power through Armistice Capital Master Fund Ltd., where Armistice Capital acts as the …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. LiveRamp Holdings (RAMP) drew investor attention after reporting first quarter results to June 30, 2026, with sales of US$213.99 million and net income …
Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader …
Verastem (VSTM) reported strong Q2 2026 results, with net product revenue of $25.1 million and total revenue of $40.1 million. The company secured $75 million in non-dilutive royalty financing and a $15 million milestone payment, extending its cash runway into the second half of …
LiveRamp Holdings, Inc. director Vivian Chow received an equity grant of 1,058 shares of common stock on August 12, 2026, as part of her compensation for service. These shares were issued at $0.00 per share, increasing her directly held position to 31,263 shares. The …
Vivian Chow, a director at LiveRamp Holdings, Inc. (NYSE: RAMP), received 1,058 shares of common stock on August 12, 2026, as compensation for her board service. This transaction increases her direct beneficial ownership to 31,263 shares. The shares were granted at no cost, indicating …
LiveRamp Holdings, Inc. director Debora B. Tomlin was granted an equity compensation award of 1,058 shares of common stock on August 12, 2026, as part of her compensation for board service. These shares were issued at $0.00 per share, increasing her directly held stake …
LiveRamp Holdings, Inc. director Timothy R. Cadogan was granted 1,058 shares of common stock as part of his compensation for board service, increasing his direct holdings to 62,157 shares. The shares were awarded at $0.00 per share, as detailed in a recent Form 4 …
Spotting Winners: Molson Coors (NYSE:TAP) And Beverages, Alcohol, and Tobacco Stocks In Q2 Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Molson Coors (NYSE:TAP) and its peers. These companies' …
Shares of Monster Beverage Corp. (MNST) rose 1.52% to $46.68 on Thursday, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also saw gains. This marked the second consecutive day of increases for the stock. The article highlights Monster …
Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The …
AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …
Search by ticker symbol or company name and select a result to open its chart.